Evidence map›Paper›PMID 41585042›Full record

ArticleRegenerative therapy2026

Tissue and organ engineering: Investor sentiments and analysis.

Frida Velcani, Erica Keyes, José Luis Caraveo, James Reohr, Craig D'Cruz, Andrew Osterman, Deirdre C O'Donnell

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Regenerative therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Frida VelcaniTuck School of Business at Dartmouth, 100 Tuck Hall, Hanover, NH, 03755, USA.
Erica KeyesTuck School of Business at Dartmouth, 100 Tuck Hall, Hanover, NH, 03755, USA.
José Luis CaraveoTuck School of Business at Dartmouth, 100 Tuck Hall, Hanover, NH, 03755, USA.
James ReohrTuck School of Business at Dartmouth, 100 Tuck Hall, Hanover, NH, 03755, USA.
Craig D'CruzTuck School of Business at Dartmouth, 100 Tuck Hall, Hanover, NH, 03755, USA.
Andrew OstermanAdvanced Regenerative Manufacturing Institute, Technology Center, 400 N Commercial St, Manchester, NH, 03101, USA.
Deirdre C O'DonnellTuck School of Business at Dartmouth, 100 Tuck Hall, Hanover, NH, 03755, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Regenerative medicine involves restoring natural function by replacing or regenerating human cells, tissues, or organs. Despite projections of significant market growth, venture capital (VC) investment in tissue and organ engineering has recently declined. Methods: We conducted a mixed-methods study using structured surveys and qualitative interviews. VC investors with experience in healthcare sectors (biotechnology, tissue engineering, and medical technology) were invited to complete a survey and participate in interviews. Results: We received 22 survey responses and conducted 9 interviews (April-May 2025). Prior exposure to regenerative medicine was significantly associated with future investment likelihood (p = 0.0464). Investment potential strongly correlated with assets under management (ρ = 0.67) and investment stage (ρ = 0.66). Among 20 respondents, clinical validation (n = 8) and adoption (n = 8) were most often cited as major investment drivers, followed by reimbursement and regulatory challenges. Interviews emphasized four factors shaping VC interest in tissue and organ engineering: prior investment experience, time horizon misalignment, clinical risk expectations, and market readiness. Discussion: Startups can improve appeal by targeting long-horizon investors, outlining clinical and regulatory pathways, and generating robust, comparative evidence to support value-based reimbursement.

Indexed as

BiotechnologyMedical technologyOrgan engineeringRegenerative medicineTissue engineeringVenture capital

Identifiers

PMID41585042
PMCPMC12828420

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.